TechnoPhage, a clinical-stage biopharmaceutical company specializing in the development of phage treatments targeting specific pathogenic bacteria, has announced, following the successful conclusion of the Phase 1 study in 2022, the initiation of Phase 2b study (REVERSE 2) for TP-102, a phage therapy candidate designed to address Diabetic Foot Infections.

The phage cocktail developed by TechnoPhage specifically targets strains of Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baumannii, known to cause foot infections. These infections often contribute to the overall morbidity and mortality of diabetic patients who, in many cases, struggle to find effective solutions through current treatment approaches.

“This exciting new phase emphasizes our commitment to innovation, clinical excellence, and the potential to revolutionize the treatment of these infections. It strengthens TechnoPhage’s mission to contribute to the redefinition of the future of biopharmaceuticals” pointed out Miguel Garcia, CEO of Technophage.

The research involves 80 participants and constitutes an international, multicenter, double-blinded, randomized, and placebo-controlled study. Its primary objectives are to evaluate the safety and tolerability of TP-102, assess clinical enhancements in individuals with diabetic foot infections, and investigate the influence of TP-102 on the process of wound healing.